Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea

M. Marchini, L. Fedele, U. Garagiola, V. Maresca

Research output: Contribution to journalArticle

Abstract

In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p

Original languageEnglish
Pages (from-to)699-705
Number of pages7
JournalDrugs under Experimental and Clinical Research
Volume13
Issue number11
Publication statusPublished - 1987

Fingerprint

Dysmenorrhea
Naproxen
Placebos
Capsules
Therapeutics
Blindness
Menstrual Cycle
Random Allocation
pirprofen
Clinical Trials

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea. / Marchini, M.; Fedele, L.; Garagiola, U.; Maresca, V.

In: Drugs under Experimental and Clinical Research, Vol. 13, No. 11, 1987, p. 699-705.

Research output: Contribution to journalArticle

Marchini, M. ; Fedele, L. ; Garagiola, U. ; Maresca, V. / Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea. In: Drugs under Experimental and Clinical Research. 1987 ; Vol. 13, No. 11. pp. 699-705.
@article{411dc6de060e44fea0c14dfcd1de4cab,
title = "Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea",
abstract = "In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p",
author = "M. Marchini and L. Fedele and U. Garagiola and V. Maresca",
year = "1987",
language = "English",
volume = "13",
pages = "699--705",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "11",

}

TY - JOUR

T1 - Pirprofen, naproxen and placebo in the treatment of primary dysmenorrhoea

AU - Marchini, M.

AU - Fedele, L.

AU - Garagiola, U.

AU - Maresca, V.

PY - 1987

Y1 - 1987

N2 - In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p

AB - In a double-blind between-patient clinical trial, 82 patients were admitted to the study and after a preliminary period with placebo administered in single-blindness, they were divided into two groups: 'placebo-responders' and 'placebo non-responders'. Responders were treated with pirprofen capsules (400 mg, b.i.d.) or placebo capsules b.i.d.; non-responders were treated with pirprofen capsules (400 mg, b.i.d.) or naproxen capsules (250 mg, b.i.d.) according to two different randomisation lists, for four menstrual cycles. A complete medical examination, including evaluation of associated symptomatology, menstrual flow entity and global efficacy, was performed after each cycle. In the responders group results were significantly better with pirprofen than with placebo after only the second cycle of treatment (p

UR - http://www.scopus.com/inward/record.url?scp=0023597221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023597221&partnerID=8YFLogxK

M3 - Article

C2 - 3327669

AN - SCOPUS:0023597221

VL - 13

SP - 699

EP - 705

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 11

ER -